Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039537 | 0.77 | EGFR (0.48) | PPIAEGFRERBB2SYKSIRT2 | |
| SCHEMBL13763843 | 0.75 | GSK3A (0.47) | PPIAXDHEGFRERBB2SYK | |
| SCHEMBL5546967 | 0.70 | XDH (0.52) | XDH | |
| SCHEMBL5545433 | 0.69 | XDH (0.48) | PPIAXDH | |
| SCHEMBL5550158 | 0.69 | XDH (0.51) | PPIAXDH | |
| SCHEMBL5046278 | 0.69 | CDK19 (0.53) | PPIASYKSIRT2SIRT1SIRT3 | |
| SCHEMBL5039422 | 0.67 | PPIA (0.53) | PPIASYK | |
| SCHEMBL6024058 | 0.67 | AURKA (0.50) | PPIA | |
| SCHEMBL5545418 | 0.66 | PPIA (0.49) | PPIAEGFRERBB2SIRT2 | |
| SCHEMBL5544745 | 0.65 | XDH (0.49) | PPIAXDHEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | PPIA 3692/4885XDH 189/4885EGFR 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.